OH

Targeting tumor associated macrophages in immunotherapy resistant NSCLC

Partner Awards
Grant title (if any)
Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy
Dwight Owen, MD, MSc
The Ohio State University
Columbus
OH

This project will investigate the role of cells called macrophages, key components of the immune system that have multiple functions, including immune surveillance within a unique communication pathway called hedgehog (Hh). The hedgehog signaling pathway is involved in cell growth and differentiation, as well as maintenance of stem cells and tissue repair. Disruption or inhibition of Hh can create an environment that is less favorable for survival of cancer cells, allowing a patient’s immune system to combat it more effectively.  This research has the potential to benefit patients who have been diagnosed with NSCLC, who have not responded to current treatments including immunotherapy by boosting the body’s own defense mechanisms.

Research Summary

Lung cancer remains one of the most lethal types of cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for a majority of cases. The goal of our research is to better understand the relationship between certain immune cells called macrophages and NSCLC, and how this interaction contributes to the cancer's survival and resistance to treatment. The scientific premise of our project lies in investigating a unique communication pathway known as hedgehog signaling within these macrophages and determining how it impacts the immune system's ability to fight lung cancer. If successful, our research has the potential to benefit patients who have been diagnosed with NSCLC, particularly those who have not responded to current treatments including treatment with immune therapies. By disrupting the hedgehog signaling pathway in macrophages, we hope to create a tumor immune environment that is less favorable for cancer cell survival, allowing patients' immune systems to effectively combat the disease. This research can pave the way for innovative therapeutic approaches that boost the body's own defense mechanisms.

Technical Abstract

The prognosis for patients with metastatic non-small cell lung cancer (NSCLC) remains poor despite recent progress in immune checkpoint blockade (ICB) therapy. Thus, there is an urgent need to understand mechanisms for lung cancer immune evasion within the tumor microenvironment (TME) in order to develop more effective and durable strategies for treating lung cancer. Tumor associated macrophages (TAMs), a major component of the tumor stromal mass, generally display an anti-inflammatory phenotype and can facilitate tumor growth by promoting angiogenesis, invasion, and metastasis, as well as immune evasion. However, it remains largely undefined exactly how these TAMs regulate anti-tumor immune responses within the TME. Will test the hypothesis that hedgehog signaling in TAMs interferes with recruitment of CD8+ T cells to the TME through the following specific aims: 1) Investigate the role of Hh inhibition with anti-PD-L1 therapy in non-small cell lung cancer; 2) Study the impact of Hh inhibition on TAMs and changes within the TME. The objective of this project is to understand signals required for functional polarization of TAMs within the TME and its contributions to immune cell dysregulation and cancer progression, and whether combined Hh inhibition and ICB can overcome resistance to immunotherapy.

Radiogenomic Biomarker and Multiomic Data Integration to Predict Radiation Response in Lung Cancer

Partner Awards
Grant title (if any)
ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant
Funded by the American Society for Radiation Oncology
Kailin Yang, MD, PhD
Cleveland Clinic Foundation
Cleveland
OH

Radiation therapy remains a cornerstone treatment for patients with locally advanced lung cancer, however knowing which patients will respond and which will not respond is still poorly understood.  The goal of this project is to analyze genomic and radiomic data from patients with NSCLC to understand how tumors change during therapy and create models to predict therapeutic response that will assist with clinical decision making.

Targeting myeloid-derived suppressor cells in lung cancer

Career Development Award
Dwight Owen, MD
The Ohio State University Comprehensive Cancer Center
Columbus
OH

Immunotherapy has become a standard treatment regimen for advanced-stage non-small cell lung cancer. However, most patients do not respond. One significant barrier to immunotherapy efficacy is the tumor microenvironment (TME), which contains immunosuppressive cells, including myeloid-derived suppressor cells (MDSCs). MDSCs represent an important tumor immune escape mechanism and play a role in the development and progression of lung cancer. Dr. Owen will be studying how this group of cells can be targeted to improve the effect of immunotherapy.

Circulating miRNA as a biomarker in lung cancer

Early Detection Research Award
Funded by LUNGevity Foundation and The CHEST Foundation
S. Patrick Nana-Sinkam, MD
The Ohio State University
Columbus
OH

Dr. Nana-Sinkam is delineating the role of microRNA expression profiling in the diagnosis, management, and prognosis of lung cancer. He is testing whether microRNA expression profiles are detectable in the  blood of lung cancer patients. He will compare individuals with lung cancer with current and former smokers without lung cancer.

Treatment of Spontaneous Non Small Cell Lung Cancer in Transgenic Mice with PRIMA-1, a Novel Anti Cancer Agent

Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and Joan's Legacy
Wenrui Duan, PhD
Ohio State University
Columbus
OH

The p53 gene can stop cells from becoming cancerous. It is mutated in non-small cell lung cancer, allowing cancer cells to grow in an uncontrolled manner. Dr. Duan is evaluating whether a new type of targeted therapy called PRIMA-1, used alone or in combination with other chemotherapies such as cisplatin, can stop the growth of non-small cell lung cancer cells.

Identification and validation of exhaled breath biomarkers for the detection of early stage lung cancer

Early Detection Research Award
LUNGevity Foundation/Partnership for Cures Research Grant
Peter J. Mazzone, MD, MPH, FRCPC, FCCP
The Cleveland Clinic Foundation
Cleveland
OH

Dr. Mazzone is identifying exhaled breath biomarkers for the detection of early-stage lung cancer. This breath biomarker work may also lead to a new way to characterize lung cancers, determine their prognosis, and predict and monitor their response to therapy.

Biomarkers for personalizing adjuvant therapy in NSCLC – increasing cures

Targeted Therapeutics Research Award
David P. Carbone, MD, PhD
The Ohio State University
Columbus
OH
John Minna, MD
University of Texas Southwestern Medical Center
Dallas
TX
Ignacio Wistuba, MD
University of Texas MD Anderson Cancer Center
Houston
TX

Patients with stage I and II lung cancer usually undergo surgery to treat their cancer. Sometimes, the cancer comes back. Using chemotherapy with surgery can prevent the cancer’s return. Dr. Carbone is studying how we can identify which stage I and II patients may benefit from chemotherapy.